Skip to main content

Warning notification:Warning

Unfortunately, you are using an outdated browser. Please, upgrade your browser to improve your experience with HSE. The list of supported browsers:

  1. Chrome
  2. Edge
  3. FireFox
  4. Opera
  5. Safari
HSE National Clinical Guideline

Management of Infants with a Suspected Diagnosis of Spinal Muscular Atrophy (SMA) through the National Newborn Bloodspot Screening Programme (NNBSP)


Topic: Management of infants with a suspected diagnosis of spinal muscular atrophy (sma) through the national newborn bloodspot screening programme (nnbsp)
Document Owner: Chief Clinical Officer
National Group: National Clinical Programme for Paediatrics and Neonatology and Children’s Health Ireland
Effective From: 24 February 2026
The management of infants with a suspected diagnosis of Spinal Muscular Atrophy (SMA) Through the National Newborn Bloodspot Screening Programme (NNBSP)
Management of Infants with a Suspected Diagnosis of Spinal Muscular Atrophy (SMA) through the National Newborn Bloodspot Screening Programme (NNBSP)
PDF, 0.58MB

To provide an evidence-based, nationally standardised, time-critical clinical pathway for the management of infants who screen positive for a suspected diagnosis of Spinal Muscular Atrophy (SMA) through the Irish National Newborn Bloodspot Screening Programme (NNBSP).

Back to HSE National Central Repository